Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)

Background: Semaglutide is a long-acting, subcutaneous (s.c.), glucagon-like peptide-1 analogue that is currently being investigated for obesity management in adults with overweight or obesity in the phase 3 STEP clinical trial program. Varying degrees of weight loss were observed with once-weekly s...

Descripción completa

Detalles Bibliográficos
Autores principales: Suresh, Swaroop H, Kushner, Robert F, Garvey, W Timothy, Hesse, Dan, Koroleva, Anna, Lim, Soo, Lingway, Ildiko, Wallenstein, Ofri Mosenzon Signe O R, Wadden, Thomas A, Roux, Carel W Le
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Abstracts … Esicon 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067867/
http://dx.doi.org/10.4103/2230-8210.342310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067867/
http://dx.doi.org/10.4103/2230-8210.342310

Ejemplares similares